Diagnostic Approach to Acute Pulmonary Embolism
Initial Assessment and Imaging
- The European Society of Cardiology recommends a structured algorithm for diagnosing acute pulmonary embolism, including clinical probability assessment, D-dimer testing, and imaging studies, with CT pulmonary angiography (CTPA) as the first-line imaging test for suspected PE in hemodynamically stable patients 1
- Patients with shock or hypotension (high-risk PE) should be immediately identified, with systolic BP <90 mmHg or drop ≥40 mmHg for >15 min not caused by arrhythmia, hypovolemia, or sepsis, and should undergo immediate bedside echocardiography 1, 2
- Clinical features suggesting PE include dyspnea (80% of PE cases), chest pain (52% of PE cases), and other symptoms such as tachypnea, tachycardia, syncope, and hemoptysis, which are present in varying degrees in up to 97% of PE cases 3, 4
The following diagnostic tests are used to diagnose pulmonary embolism:
Diagnostic Test Description D-dimer Useful with reasonable suspicion of PE, with a negative D-dimer safely excluding PE in the appropriate clinical context, and age-adjusted D-dimer cutoffs should be used for patients over 50 years old [1, 2, 4] CTPA First-line imaging test with sensitivity 83% and specificity 96% [1] Echocardiography Essential in suspected high-risk PE [1] Leg ultrasound Alternative to lung imaging in clinical DVT, with a sensitivity and specificity of 89% and 95% respectively [5, 1, 2]
Risk Stratification and Treatment Guidance
- The European Society of Cardiology recommends using cardiac biomarkers, such as troponin, NT-proBNP/BNP, and H-FABP, for risk stratification, not diagnosis 1
- Echocardiography is essential for assessing RV function and guiding treatment decisions in suspected high-risk PE 1
- Risk stratification should be performed after confirming PE diagnosis, with high-risk patients having shock or hypotension, intermediate-risk patients having RV dysfunction and/or myocardial injury markers, and low-risk patients having no RV dysfunction or myocardial injury markers 1
- Anticoagulation therapy with direct oral anticoagulants (DOACs) or non-vitamin K antagonist oral anticoagulants (NOACs) is preferred over vitamin K antagonists for intermediate and low-risk PE, with options including apixaban, rivaroxaban, edoxaban, and dabigatran, and a Class I recommendation for NOACs over vitamin K antagonists (VKAs) for oral anticoagulation 1, 6
- Initial parenteral anticoagulation with low molecular weight heparin (LMWH) or fondaparinux is preferred over unfractionated heparin (UFH), with a target APTT of 1.5-2.5 times control (45-75 seconds) for UFH therapy 1
Alternative Diagnoses and Imaging
- Compression ultrasound of lower limbs has a sensitivity >90% and specificity ~95% for detecting DVT, and finding proximal DVT is sufficient to warrant anticoagulation without further testing 2
- Bedside echocardiography can also help identify alternative diagnoses, such as tamponade, acute valvular dysfunction, or aortic dissection 2
- The European Society of Cardiology recommends classifying clinical probability as low, intermediate, or high based on the presence of factors, and measuring D-dimer when there is reasonable suspicion of PE, with a low clinical probability classification defined as neither factor present, intermediate as one factor present, and high as both factors present 5
Treatment Options
The following therapy options are available for high-risk PE:
Therapy Description Systemic thrombolysis Alteplase 100 mg administered over 2 hours, with a strength of evidence level of 1B [2] Surgical embolectomy Recommended when thrombolysis is contraindicated or has failed, with a Class IIa recommendation [2] Percutaneous interventions Alternative when surgical options are not available, with a Class IIb recommendation [2] ECMO Considered in cases of refractory circulatory collapse or cardiac arrest, with a Class IIb recommendation [2] Thrombolytic therapy options and their dosages are as follows:
Agent Dosage Alteplase (rtPA) 100 mg over 2 hours or 0.6 mg/kg over 15 min (maximum dose 50 mg), with a strength of evidence level of 1B [7] Streptokinase 250,000 IU loading dose over 30 min, followed by 100,000 IU/h over 12-24h; or accelerated regimen: 1.5 million IU over 2h, with a strength of evidence level of 1B [7] Urokinase 4,400 IU/kg loading dose over 10 min, followed by 4,400 IU/kg/h over 12-24h; or accelerated regimen: 3 million IU over 2h, with a strength of evidence level of 1B [7]
Anticoagulation and Follow-up
- Minimum 3 months of anticoagulation is recommended for all patients, with extended anticoagulation considered for patients with unprovoked PE, persistent risk factors, or minor transient/reversible risk factors, as recommended by the American College of Chest Physicians and European Society of Cardiology 1, 6
- Clinical evaluation at 3-6 months after acute PE is recommended to assess for persistent symptoms, signs of recurrence, bleeding complications, and chronic thromboembolic pulmonary hypertension (CTEPH) 1
- Extended anticoagulation should be considered for unprovoked PE or persistent risk factors, and patients should be evaluated for chronic thromboembolic pulmonary hypertension (CTEPH) if they have persistent symptoms, as recommended by the American College of Chest Physicians and European Society of Cardiology 6, 1